EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Nanoenabled Strategies Enhancing PROTACs for Cancer Therapy

Rui Li iD, Shuhao Zhang, Yunxue Xu, Renfa Liu iD, Zhifei Dai iD

Bioconjugate Chemistry · 2025

DOI: 10.1021/acs.bioconjchem.5c00305 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Bioconjugate Chemistry, 2025. Verfasst von Rui Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, College of Future Technology, National Biomedical Imaging Center, State Key Laboratory of Vascular Homeostasis …. Hauptthemen laut MEDLINE: Neoplasms, Proteolysis, Nanotechnology, Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Proteolysis-targeting chimeras (PROTACs) have emerged as a breakthrough therapeutic strategy in oncology, enabling the selective degradation of traditionally "undruggable" proteins via the ubiquitin-proteasome system. However, their clinical translation remains challenging due to high molecular weight, limited aqueous solubility, and metabolic instability, which limit systemic bioavailability and tumor penetration. To address these challenges, a variety of nanocarrier systems have been developed to improve the stability, pharmacokinetics, and tumor-specific accumulation of PROTACs. Beyond delivery enhancement, nanotechnology also enables the creation of next-generation PROTAC modalities, such as mRNA-encoded and RNA-scaffolded PROTACs, thereby expanding their therapeutic potential. In parallel, stimuli-responsive nanocarriers offer spatiotemporal control over PROTAC release, maximizing therapeutic efficacy while minimizing off-target effects. This review provides a comprehensive overview of nanotechnology-enabled strategies for PROTAC delivery, highlights key translational challenges, and discusses future directions to facilitate their clinical advancement in cancer therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsProteolysisNanotechnologyAntineoplastic AgentsNanoparticlesHumansAnimalsDrug Delivery SystemsDrug CarriersProteolysis Targeting Chimera

Substanzen

Antineoplastic AgentsDrug CarriersProteolysis Targeting Chimera

Autor:innen und Institutionen

  • Department of Biomedical Engineering, College of Future Technology, National Biomedical Imaging Center, State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University, Beijing 100871, China.
  • School of Light Industry Science and Engineer, Beijing Technology and Business University, Beijing 100048, China.

ORCID-Profile: Rui Li, Renfa Liu, Zhifei Dai

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China

Zitieren

APA

Li, R., Zhang, S., Xu, Y., Liu, R., & Dai, Z. (2025). Nanoenabled Strategies Enhancing PROTACs for Cancer Therapy. Bioconjugate Chemistry. https://doi.org/10.1021/acs.bioconjchem.5c00305

Vancouver

Li R, Zhang S, Xu Y, Liu R, Dai Z. Nanoenabled Strategies Enhancing PROTACs for Cancer Therapy. Bioconjugate Chemistry. 2025. doi:10.1021/acs.bioconjchem.5c00305

BibTeX
@article{Li2025,
  author = {Li, Rui and Zhang, Shuhao and Xu, Yunxue and Liu, Renfa and Dai, Zhifei},
  title = {Nanoenabled Strategies Enhancing PROTACs for Cancer Therapy},
  journal = {Bioconjugate Chemistry},
  year = {2025},
  doi = {10.1021/acs.bioconjchem.5c00305}
}
Kostenlos starten →